StockData
Ensysce Biosciences, Inc. logo

Ensysce Biosciences, Inc. (ENSC) stock

ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.37−0.01 (-3.62%)

Close on Nov 18, 2026Market cap $7.20MP/E –Yield –

Ensysce Biosciences net income

Net income is the profit left for shareholders after every expense, interest and tax.

Ensysce Biosciences's net income for the twelve months ending Sep 30, 2021 was -$15.34M. For fiscal 2020 it was $4.31M.

Annual net income

PeriodPeriod endValueChange
FY2020Dec 31, 2020$4.31M–
FY2019Dec 31, 2019-$1.07M-150.3%
FY2018Dec 31, 2018$2.12M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2021Sep 30, 2021-$17.16M-1192.9%
Q2 FY2021Jun 30, 2021-$935.54K–
Q1 FY2021Mar 31, 2021-$1.71M-195.5%
Q4 FY2020Dec 31, 2020$4.47M–
Q3 FY2020Sep 30, 2020$1.57M+220.7%
Q2 FY2020Jun 30, 2020-$704.50K-268.2%
Q1 FY2020Mar 31, 2020$1.79M+131.0%
Q4 FY2019Dec 31, 2019-$2.75M-480.5%
Q3 FY2019Sep 30, 2019$489.72K-15.2%
Q2 FY2019Jun 30, 2019$418.90K+0.9%
Q1 FY2019Mar 31, 2019$775.91K+91.1%
Q4 FY2018Dec 31, 2018$723.21K–
Q3 FY2018Sep 30, 2018$577.65K–
Q2 FY2018Jun 30, 2018$415.11K–
Q1 FY2018Mar 31, 2018$406.07K–

More Ensysce Biosciences figures

See a number that looks wrong?